Page last updated: 2024-08-16

sulfaphenazole and omega-n-methylarginine

sulfaphenazole has been researched along with omega-n-methylarginine in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (85.71)	29.6817
2010's	1 (14.29)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Büssemaker, E; Fauler, J; Fleming, I; Gross, P; Lässig, G; Passauer, J; Pistrosch, F	1
Breuer, S; Busse, R; Dimmeler, S; Fichtlscherer, S; Fleming, I; Zeiher, AM	1
Büssemaker, E; Fleming, I; Gross, P; Herbrig, K; Lässig, G; Passauer, J; Pistrosch, F	1
Cipriano, A; Franzoni, F; Galetta, F; Ghiadoni, L; Magagna, A; Salvetti, A; Taddei, S; Versari, D; Virdis, A	1
Donato, AJ; Eskurza, I; Gano, LB; Jablonski, KL; Pierce, GL; Seals, DR	1
De Negri, F; Duranti, E; Giannarelli, C; Magagna, A; Salvetti, A; Taddei, S; Virdis, A	1
Ambrogini, E; Banti, C; Bernini, G; Carrara, D; Cetani, F; Ghiadoni, L; Giannarelli, C; Marcocci, C; Pinchera, A; Taddei, S; Virdis, A	1

Trials

2 trial(s) available for sulfaphenazole and omega-n-methylarginine

Article	Year
Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole. Clinical science (London, England : 1979), 2003, Volume: 105, Issue:4 Topics: Adult; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Bradykinin; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Forearm; Humans; Ibuprofen; Male; Nitric Oxide Synthase; omega-N-Methylarginine; Plethysmography; Regional Blood Flow; Sulfaphenazole; Vasodilator Agents	2003
Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation, 2004, Jan-20, Volume: 109, Issue:2 Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Blood Proteins; Coronary Artery Disease; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Enzyme Inhibitors; Forearm; Humans; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Oxidation-Reduction; Regional Blood Flow; Sulfaphenazole; Vasodilation; Vasodilator Agents	2004

Article

Year

Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole.

Clinical science (London, England : 1979), 2003, Volume: 105, Issue:4

Topics: Adult; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Bradykinin; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Forearm; Humans; Ibuprofen; Male; Nitric Oxide Synthase; omega-N-Methylarginine; Plethysmography; Regional Blood Flow; Sulfaphenazole; Vasodilator Agents

2003

Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.

Circulation, 2004, Jan-20, Volume: 109, Issue:2

Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Blood Proteins; Coronary Artery Disease; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Enzyme Inhibitors; Forearm; Humans; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Oxidation-Reduction; Regional Blood Flow; Sulfaphenazole; Vasodilation; Vasodilator Agents

2004

Other Studies

5 other study(ies) available for sulfaphenazole and omega-n-methylarginine

Article	Year
Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9. Kidney international, 2005, Volume: 67, Issue:5 Topics: Acetylcholine; Adult; Arterioles; Aryl Hydrocarbon Hydroxylases; Biological Factors; Case-Control Studies; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Enzyme Inhibitors; Humans; Male; Nitric Oxide; Nitric Oxide Synthase; Nitroprusside; omega-N-Methylarginine; Sulfaphenazole; Uremia; Vasodilation; Vasodilator Agents	2005
Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. Journal of the American College of Cardiology, 2006, Aug-01, Volume: 48, Issue:3 Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Biological Factors; Bradykinin; Case-Control Studies; Cytochrome P-450 CYP2C9; Drug Combinations; Drug Synergism; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Humans; Hypertension; Male; Microcirculation; Middle Aged; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Sulfaphenazole; Vasodilation; Vasodilator Agents	2006
Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans. Journal of applied physiology (Bethesda, Md. : 1985), 2008, Volume: 105, Issue:4 Topics: Acetylcholine; Adult; Age Factors; Aged; Aging; Aryl Hydrocarbon Hydroxylases; Brachial Artery; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Humans; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Nitroprusside; omega-N-Methylarginine; Oxidative Stress; Regional Blood Flow; Signal Transduction; Sulfaphenazole; Vasodilation; Vasodilator Agents	2008
Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients. Circulation, 2009, Mar-31, Volume: 119, Issue:12 Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Blood Pressure; Bradykinin; Case-Control Studies; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Female; Forearm; Humans; Hypertension; Male; Microcirculation; Middle Aged; omega-N-Methylarginine; Sulfaphenazole; Tissue Plasminogen Activator	2009
The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:2 Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Biological Factors; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Female; Humans; Hyperparathyroidism, Primary; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Parathyroidectomy; Sulfaphenazole; Vasodilation	2010